Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Intern Med ; 54(13): 1661-4, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26134202

RESUMO

The absence of meningeal signs and symptoms is rare in patients with bacterial meningitis and may lead to a delay in diagnosis and treatment. Furthermore, the onset of bacterial meningitis associated with pneumocephalus is a rare complication of ear infections. We herein report a rare case of otogenic meningitis complicated by pneumocephalus that was initially missed due to the absence of typical meningeal signs and symptoms and later diagnosed correctly based on a thorough review of the patient's systems.


Assuntos
Bacteriemia/diagnóstico , Bacteriemia/microbiologia , Meningites Bacterianas/diagnóstico , Meningite Pneumocócica/diagnóstico , Pneumocefalia/diagnóstico , Adulto , Antibacterianos/administração & dosagem , Bacteriemia/tratamento farmacológico , Bacteriemia/etiologia , Dexametasona/administração & dosagem , Humanos , Masculino , Meningite Pneumocócica/complicações , Meningite Pneumocócica/tratamento farmacológico , Meropeném , Pneumocefalia/tratamento farmacológico , Pneumocefalia/etiologia , Tienamicinas/administração & dosagem , Resultado do Tratamento , Vancomicina/administração & dosagem
2.
Int Immunopharmacol ; 7(12): 1569-76, 2007 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-17920534

RESUMO

We investigated the bucillamine (Buc) mechanism inhibiting interleukin (IL)-1beta-induced vascular endothelial growth factor (VEGF) production from human fibroblast-like synoviocytes (HFLS) which derived from the inflamed synovium of an RA patient using SA981, its active metabolite. HFLS did not produce IL-1beta, spontaneously. While SA981 partially inhibited IL-1beta-induced VEGF production at concentrations of 10 to 100 microM (10.1% and 14.2% inhibition of total VEGF production under IL-1beta coexistence condition, respectively), it failed to inhibit IL-1beta-induced IL-6 production at the same concentrations. IL-1beta induced phosphorylation of the mitogen-activated protein (MAP) kinases, IkappaBalpha, c-Jun and Akt. SA981 at a concentration of 100 microM partially inhibited IL-1beta-induced phosphorylation of p38MAPK and Akt (12.0% and 36.1% inhibition of each total amount of phosphoprotein under IL-1beta coexistence condition, respectively). The VEGF promoter includes four transcription factors: AP1, hypoxia-inducible factor (HIF), Sp1 and AP2 binding elements. HIF-1beta, Sp1 and AP1 increased under IL-1beta coexistence conditions. At a concentration of 100 microM, SA981 attenuated increases in HIF-1beta and Sp1 (10.1% and 19.8% inhibition of each total amount of transcription factor under IL-1beta coexistence condition, respectively), but not AP1. These results suggest that SA981 partially inhibits VEGF production via modifications on IL-1beta signaling. Attenuation of the expression of HIF-1beta and Sp1 (but not AP1) may be a key with respect to SA981's selective inhibition of VEGF production.


Assuntos
Cisteína/análogos & derivados , Fibroblastos/efeitos dos fármacos , Interleucina-1beta/farmacologia , Membrana Sinovial/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/metabolismo , Anti-Inflamatórios não Esteroides/farmacologia , Translocador Nuclear Receptor Aril Hidrocarboneto/metabolismo , Linhagem Celular , Cisteína/farmacologia , Relação Dose-Resposta a Droga , Fibroblastos/citologia , Fibroblastos/metabolismo , Humanos , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Proteínas I-kappa B/metabolismo , Interleucina-6/metabolismo , Interleucina-6/farmacologia , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Inibidor de NF-kappaB alfa , Fosforilação/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-akt/metabolismo , Proteínas Proto-Oncogênicas c-jun/metabolismo , Fator de Transcrição Sp1/metabolismo , Membrana Sinovial/citologia , Membrana Sinovial/metabolismo , Fator de Transcrição AP-1/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA